- Trials with a EudraCT protocol (458)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
458 result(s) found for: Peripheral Neuropathy.
Displaying page 9 of 23.
EudraCT Number: 2015-001755-72 | Sponsor Protocol Number: GBG88 | Start Date*: 2016-11-22 | |||||||||||
Sponsor Name:German Breast Group | |||||||||||||
Full Title: Investigating Denosumab as an add-on to neoadjuvant chemotherapy in RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules in a 2x2 factorial design (Ge... | |||||||||||||
Medical condition: Patients with early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006791-12 | Sponsor Protocol Number: Fx1A-201 | Start Date*: 2008-04-02 |
Sponsor Name:FoldRx Pharmaceuticals Limited | ||
Full Title: The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis | ||
Medical condition: Non-V30M Transthyretin Amyloidosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-021430-64 | Sponsor Protocol Number: RR10/9389 | Start Date*: 2010-12-03 | |||||||||||
Sponsor Name:University of Leeds | |||||||||||||
Full Title: A randomised double blind placebo controlled clinical trial of anti B-cell therapy in patients with primary Sjögren’s syndrome. | |||||||||||||
Medical condition: Primary Sjögren’s syndrome (PSS). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002602-12 | Sponsor Protocol Number: 16/SEP/6613E | Start Date*: 2018-01-12 |
Sponsor Name:Cardiff and Vale University Health Board | ||
Full Title: Improving Transplant Opportunities for Patients who are Sensitised (ITOPS) – a feasibility, randomised, controlled phase III trial | ||
Medical condition: Highly Sensitised Patients(patients with high levels of human leucocyte antigen specific antibodies) awaiting renal transplantation.These patients are difficult to match to a compatible donor and t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000513-39 | Sponsor Protocol Number: LIN-interaction-01 | Start Date*: 2011-07-27 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: The pharmacokinetic effect of clarithromycin on the AUC0-12h of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients | |||||||||||||
Medical condition: Multidrug-resistant and extensively drug-resistant tubeculosis (MDR/XDR-TB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002591-14 | Sponsor Protocol Number: CTC0128 | Start Date*: 2020-05-29 | |||||||||||
Sponsor Name:Belfast Health & Social Care Trust | |||||||||||||
Full Title: The Fenofibrate And Microvascular Events in Type 1 diabetes Eye (FAME 1 Eye): A randomised trial to evaluate the efficacy on retinopathy and safety of fenofibrate in adults with type 1 diabetes. A... | |||||||||||||
Medical condition: To evaluate the effects of once daily oral fenofibrate compared with placebo on clinically meaningful retinopathy progression over at least 3 years in adults with Type 1 diabetes (T1D) and existing... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004449-28 | Sponsor Protocol Number: PRODIGE37 | Start Date*: 2015-02-05 | |||||||||||
Sponsor Name:Fédération Francophone de Cancérologie Digestive | |||||||||||||
Full Title: A randomized multicenter phase II trial of a sequential chemotherapy of nab-paclitaxel + gemcitabine followed by FOLFIRI.3 versus nab-paclitaxel + gemcitabine in first line of pancreatic adenocarci... | |||||||||||||
Medical condition: pancreas adenocarcinoma metastatic | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005660-86 | Sponsor Protocol Number: 06_DOG03_107 | Start Date*: 2006-07-19 |
Sponsor Name:Christie Hospital NHS Trust | ||
Full Title: A Phase II, open label, single arm study to evaluate Ticilimumab in Advanced Gastric/Oesophageal Adenocarcinoma | ||
Medical condition: Advanced Gastric/Oesophageal Adenocarcinoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000067-29 | Sponsor Protocol Number: 310101 | Start Date*: 2006-07-04 |
Sponsor Name:Bayer Schering Pharma AG | ||
Full Title: Phase I/II study to investigate the safety, tolerability, efficacy and pharmacokinetics of ZK 219477 in combination with cisplatin as first-line therapy in chemotherapy-naive patients with extensiv... | ||
Medical condition: Extensive disease (ED) stage small-cell lung cancer (SCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000267-29 | Sponsor Protocol Number: 0059718/05GENII6A | Start Date*: 2006-01-01 | |||||||||||
Sponsor Name:Centro sociale oncologico | |||||||||||||
Full Title: Adjuvant chemotherapy in stage III colon carcinoma in patients age or 70 years. Feasibility of CAPOX scheme oxaliplatin 70 mg/mq days 1-8 and capecitabine 1000 mg/mq X 2 die days 1-14 every 21 da... | |||||||||||||
Medical condition: Colon carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000086-38 | Sponsor Protocol Number: FARM6KMZFY | Start Date*: 2008-04-10 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: A PHASE 2, SINGLE ARM, MULTI-CENTER STUDY ON THE BENEFIT/COST/SAFETY PROFILE OF LOW-DOSE RITUXIMAB FOR REFRACTORY MIXED CRYOGLOBULINEMIA | |||||||||||||
Medical condition: Mixed cryoglobulinemia (type II or III) associated with chronic HCV infection (positive serology and/or HCV viremia) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001508-38 | Sponsor Protocol Number: ST 200-DM-03-005 | Start Date*: 2006-03-21 | |||||||||||
Sponsor Name:SIGMA-TAU | |||||||||||||
Full Title: Phase II Explorative Study of Acetyl-L-Carnitine (ST 200) for Vincristine-Induced Neurotoxicity in Patients With Acute Lymphoblastic Leukemia (ALL). | |||||||||||||
Medical condition: Treatment of peripheral sensitive neuropathy vinca alkaloid chemotherapy -induced. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000586-19 | Sponsor Protocol Number: 307971 | Start Date*: 2005-07-25 |
Sponsor Name:Bayer Schering Pharma AG | ||
Full Title: Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC) | ||
Medical condition: Non small cell lung cancer (NSCLC) stage IIIB or stage IV | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-001118-15 | Sponsor Protocol Number: APL-B-005-02 | Start Date*: 2004-10-27 |
Sponsor Name:Pharma Mar, S.A | ||
Full Title: Phase II multicenter,open-label, clinical and pharmacokinetic study of Aplidin® as a 3-hour infusion every 2 weeks, in patients with advanced or metastatic transitional cell carcinoma of the uroth... | ||
Medical condition: More than 90% of bladder carcinomas are transitional cell carcinomas (TCC) derived from the uroepithelium. About 6% to 8% are squamous cell carcinomas, and 2% are adenocarcinomas. Adenocarcinomas ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003752-21 | Sponsor Protocol Number: MK-7902-011 | Start Date*: 2019-05-02 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line... | |||||||||||||
Medical condition: Advanced/unresectable or metastatic urothelial carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Completed) PL (Completed) NL (Completed) DK (Prematurely Ended) ES (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010980-18 | Sponsor Protocol Number: APL-B-019-08 | Start Date*: 2009-06-29 | |||||||||||
Sponsor Name:Pharma Mar, S.A. | |||||||||||||
Full Title: Efficacité et Tolérance de la Plitidepsine chez les patients souffrant d’un liposarcome dédifférencié (DLPS) avancé, non opérable ou métastatique, en rechute/réfractaire : Une étude exploratoire mu... | |||||||||||||
Medical condition: DEDIFFERENTIATED LIPOSARCOMA (DLPS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002092-42 | Sponsor Protocol Number: KF6010/01 | Start Date*: 2011-11-04 | |||||||||||
Sponsor Name:Grünenthal GmbH | |||||||||||||
Full Title: Evaluation of the efficacy, tolerability, and safety of 7 days of treatment with GRT6010 or pregabalin in comparison to placebo in subjects with peripheral neuropathic pain. | |||||||||||||
Medical condition: mononeuropathic pain due to post-herpetic neuralgia, post-operative neuropathic pain, or traumatic nerve injury | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) DE (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002131-32 | Sponsor Protocol Number: SP001033 | Start Date*: 2008-04-17 | |||||||||||
Sponsor Name:ASSOCIAZIONE ITALIANA PER LO STUDIO DEL DOLORE | |||||||||||||
Full Title: A RANDOMIZED, OPEN COMPARISON BETWEEN PREGABALIN/TRANSDERMAL BUPRENORPHINE AND PREGABALIN/DICLOFENAC IN CHRONIC NEUROPATHIC PAIN PATIENTS | |||||||||||||
Medical condition: PERIPHERAL NEUROPATHIC PAIN DUE TO POST-HERPETIC NEURALGIA OR DIABETIC POLYNEUROPATHY | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002483-27 | Sponsor Protocol Number: PKB116611 | Start Date*: 2012-11-07 | |||||||||||
Sponsor Name:Accenture | |||||||||||||
Full Title: An Open-Label Phase I/II Study of GSK2110183 in Combination with Carboplatin and Paclitaxel in Subjects with Platinum-Resistant Ovarian Cancer | |||||||||||||
Medical condition: Ovarian Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005008-32 | Sponsor Protocol Number: ICORG13-17 | Start Date*: 2014-07-16 |
Sponsor Name:Cancer Trials Ireland | ||
Full Title: A phase II Study of the Efficacy and Safety of lenalidomide, subcutaneous bortezomib, and dexamethasone combination therapy for patients with newly diagnosed multiple myeloma | ||
Medical condition: Newly diagnosed multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
